Mutant p53 Reprograms TNF Signaling in Cancer Cells through Interaction with the Tumor Suppressor DAB2IP

Molecular Cell

Volumn 56, Issue 5, 2014, Pages 617-629

  Di Minin, Giulio ^a   Bellazzo, Arianna ^a,b   DalFerro, Marco ^a,b   Chiaruttini, Giulia ^c   Nuzzo, Simona ^d   Bicciato, Silvio ^d   Piazza, Silvano ^a   Rami, Damiano ^b   Bulla, Roberta ^b   Sommaggio, Roberta ^e   Rosato, Antonio ^e,f   DelSal, Giannino ^a,b   Collavin, Licio ^a,b  

^a CBM Srl Area Science Park   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; CYTOPLASM PROTEIN; DAB2IP PROTEIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL; CYTOKINE PRODUCTION; CYTOPLASM; ENZYME ACTIVATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; PANCREAS CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENETICS; HCT116 CELL LINE; HUMAN; LYMPH NODE METASTASIS; METABOLISM; MISSENSE MUTATION; MOUSE; PATHOLOGY; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOPLASM; FEMALE; HCT116 CELLS; HUMANS; LYMPHATIC METASTASIS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, SCID; MUTATION, MISSENSE; RAS GTPASE-ACTIVATING PROTEINS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84919480782     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2014.10.013     Document Type: Article

References (46)

1. Adorno M., Cordenonsi M., Montagner M., Dupont S., Wong C., Hann B., Solari A., Bobisse S., Rondina M.B., Guzzardo V., et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009, 137:87-98.
2. Bindea G., Mlecnik B., Tosolini M., Kirilovsky A., Waldner M., Obenauf A.C., Angell H., Fredriksen T., Lafontaine L., Berger A., et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013, 39:782-795.
3. Bjordahl R.L., Steidl C., Gascoyne R.D., Ware C.F. Lymphotoxin network pathways shape the tumor microenvironment. Curr. Opin. Immunol. 2013, 25:222-229.
4. Carey L., Winer E., Viale G., Cameron D., Gianni L. Triple-negative breast cancer: disease entity or title of convenience?. Nat. Rev. Clin. Oncol. 2010, 7:683-692.
5. Cooks T., Pateras I.S., Tarcic O., Solomon H., Schetter A.J., Wilder S., Lozano G., Pikarsky E., Forshew T., Rosenfeld N., et al. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 2013, 23:634-646.
6. Curtis C., Shah S.P., Chin S.-F., Turashvili G., Rueda O.M., Dunning M.J., Speed D., Lynch A.G., Samarajiwa S., Yuan Y., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352. METABRIC Group.
7. Dong P., Xu Z., Jia N., Li D., Feng Y. Elevated expression of p53gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway. Mol. Cancer 2009, 8:103.
8. Dote H., Toyooka S., Tsukuda K., Yano M., Ouchida M., Doihara H., Suzuki M., Chen H., Hsieh J.T., Gazdar A.F., Shimizu N. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin. Cancer Res. 2004, 10:2082-2089.
9. Duffy M.J., Maguire T.M., Hill A., McDermott E., O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000, 2:252-257.
10. Finak G., Bertos N., Pepin F., Sadekova S., Souleimanova M., Zhao H., Chen H., Omeroglu G., Meterissian S., Omeroglu A., et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 2008, 14:518-527.
11. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N.Engl. J. Med. 2010, 363:1938-1948.
12. Fridman W.H., Pagès F., Sautès-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 2012, 12:298-306.
13. Galon J., Angell H.K., Bedognetti D., Marincola F.M. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013, 39:11-26.
14. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
15. Hsieh M.J., Chen K.S., Chiou H.L., Hsieh Y.S. Carbonic anhydrase XII promotes invasion and migration ability of MDA-MB-231 breast cancer cells through the p38 MAPK signaling pathway. Eur. J. Cell Biol. 2010, 89:598-606.
16. Lee H.J., Seo J.-Y., Ahn J.-H., Ahn S.-H., Gong G. Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients. J.Breast Cancer 2013, 16:32-39.
17. Lowe J., Shatz M., Resnick M., Menendez D. Modulation of immune responses by the tumor suppressor p53. BioDiscovery 2013, 8:2. 10.7750/BioDiscovery.2013.8.2.
18. Lujambio A., Akkari L., Simon J., Grace D., Tschaharganeh D.F., Bolden J.E., Zhao Z., Thapar V., Joyce J.A., Krizhanovsky V., Lowe S.W. Non-cell-autonomous tumor suppression by p53. Cell 2013, 153:449-460.
19. Lunardi A., Di Minin G., Provero P., Dal Ferro M., Carotti M., Del Sal G., Collavin L. A genome-scale protein interaction profile of Drosophila p53 uncovers additional nodes of the human p53 network. Proc. Natl. Acad. Sci. USA 2010, 107:6322-6327.
20. Miller T.W., Balko J.M., Ghazoui Z., Dunbier A., Anderson H., Dowsett M., González-Angulo A.M., Mills G.B., Miller W.R., Wu H., et al. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. Clin. Cancer Res. 2011, 17:2024-2034.
21. Min W., Lin Y., Tang S., Yu L., Zhang H., Wan T., Luhn T., Fu H., Chen H. AIP1 recruits phosphatase PP2A to ASK1 in tumor necrosis factor-induced ASK1-JNK activation. Circ. Res. 2008, 102:840-848.
22. Min J., Zaslavsky A., Fedele G., McLaughlin S.K., Reczek E.E., De Raedt T., Guney I., Strochlic D.E., Macconaill L.E., Beroukhim R., et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat. Med. 2010, 16:286-294.
23. Moustakas A., Pardali K., Gaal A., Heldin C.H. Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol. Lett. 2002, 82:85-91.
24. Muller P.A.J., Vousden K.H. p53 mutations in cancer. Nat. Cell Biol. 2013, 15:2-8.
25. Muthuswamy R., Berk E., Junecko B.F., Zeh H.J., Zureikat A.H., Normolle D., Luong T.M., Reinhart T.A., Bartlett D.L., Kalinski P. NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic Teffector cells. Cancer Res. 2012, 72:3735-3743.
26. Oren M., Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb. Perspect. Biol. 2010, 2:a001107.
27. Qiu G.-H., Xie H., Wheelhouse N., Harrison D., Chen G.G., Salto-Tellez M., Lai P., Ross J.A., Hooi S.C. Differential expression of hDAB2IPA and hDAB2IPB in normal tissues and promoter methylation of hDAB2IPA in hepatocellular carcinoma. J.Hepatol. 2007, 46:655-663.
28. Rody A., Holtrich U., Pusztai L., Liedtke C., Gaetje R., Ruckhaeberle E., Solbach C., Hanker L., Ahr A., Metzler D., et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res. 2009, 11:R15.
29. Rody A., Karn T., Liedtke C., Pusztai L., Ruckhaeberle E., Hanker L., Gaetje R., Solbach C., Ahr A., Metzler D., et al. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res. 2011, 13:R97.
30. Rustighi A., Zannini A., Tiberi L., Sommaggio R., Piazza S., Sorrentino G., Nuzzo S., Tuscano A., Eterno V., Benvenuti F., et al. Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast. EMBO Mol Med 2014, 6:99-119.
31. Sauer L., Gitenay D., Vo C., Baron V.T. Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells. Oncogene 2010, 29:2628-2637.
32. Schmidt M., Böhm D., von Törne C., Steiner E., Puhl A., Pilch H., Lehr H.A., Hengstler J.G., Kölbl H., Gehrmann M. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008, 68:5405-5413.
33. Schneider G., Henrich A., Greiner G., Wolf V., Lovas A., Wieczorek M., Wagner T., Reichardt S., von Werder A., Schmid R.M., et al. Crosstalk between stimulated NF-kappaB and the tumor suppressor p53. Oncogene 2010, 29:2795-2806.
34. Schwitalla S., Ziegler P.K., Horst D., Becker V., Kerle I., Begus-Nahrmann Y., Lechel A., Rudolph K.L., Langer R., Slotta-Huspenina J., et al. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell 2013, 23:93-106.
35. Shin S.Y., Nam J.S., Lim Y., Lee Y.H. TNFα-exposed bone marrow-derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokines. J.Biol. Chem. 2010, 285:30731-30740.
36. Solomon H., Madar S., Rotter V. Mutant p53 gain of function is interwoven into the hallmarks of cancer. J.Pathol. 2011, 225:475-478.
37. Solomon H., Buganim Y., Kogan-Sakin I., Pomeraniec L., Assia Y., Madar S., Goldstein I., Brosh R., Kalo E., Beatus T., et al. Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature. J.Cell Sci. 2012, 125:3144-3152.
38. Wajant H., Pfizenmaier K., Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003, 10:45-65.
39. Walerych D., Napoli M., Collavin L., Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 2012, 33:2007-2017.
40. Weisz L., Damalas A., Liontos M., Karakaidos P., Fontemaggi G., Maor-Aloni R., Kalis M., Levrero M., Strano S., Gorgoulis V.G., et al. Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res. 2007, 67:2396-2401.
41. Xie D., Gore C., Zhou J., Pong R.C., Zhang H., Yu L., Vessella R.L., Min W., Hsieh J.T. DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proc. Natl. Acad. Sci. USA 2009, 106:19878-19883.
42. Xie D., Gore C., Liu J., Pong R.C., Mason R., Hao G., Long M., Kabbani W., Yu L., Zhang H., et al. Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc. Natl. Acad. Sci. USA 2010, 107:2485-2490.
43. Xin H., Kikuchi T., Andarini S., Ohkouchi S., Suzuki T., Nukiwa T., Huqun, Hagiwara K., Honjo T., Saijo Y. Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and Tcells. Eur. J. Immunol. 2005, 35:1371-1380.
44. Yeudall W.A., Vaughan C.A., Miyazaki H., Ramamoorthy M., Choi M.-Y., Chapman C.G., Wang H., Black E., Bulysheva A.A., Deb S.P., et al. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis 2012, 33:442-451.
45. Zhang R., He X., Liu W., Lu M., Hsieh J.T., Min W. AIP1 mediates TNF-alpha-induced ASK1 activation by facilitating dissociation of ASK1 from its inhibitor 14-3-3. J.Clin. Invest. 2003, 111:1933-1943.
46. Zhang H., Zhang R., Luo Y., D'Alessio A., Pober J.S., Min W. AIP1/DAB2IP, a novel member of the Ras-GAP family, transduces TRAF2-induced ASK1-JNK activation. J.Biol. Chem. 2004, 279:44955-44965.